Enliven Therapeutics, Inc. 4

Chief Medical Officer Helen Louise Collins of Enliven Therapeutics, Inc. exercised 5,000 stock options at $2.48 and sold 5,000 common shares around $58–$59 per share under a Rule 10b5-1 plan, ending with 25,000 shares held.

On August 17, 2026, Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins exercised 5,000 stock options at $2.48 per share, acquiring 5,000 shares of common stock for approximately $12,400, and on the same day sold an aggregate 5,000 shares in two open-market transactions (3,900 shares at a weighted average price of $58.3717 and 1,100 shares at a weighted average price of $59.3465) for total proceeds of roughly $291,000. The option exercise and related sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2025, and appear structured as a cashless or liquidity-providing exercise while maintaining an ownership position of 25,000 shares, valued at about $1.46 million using the reported sale prices as a proxy for the current market price. Certain of the remaining holdings are in the form of RSUs, which represent contingent rights to receive shares subject to vesting, and all options exercised in this filing were already fully vested and exercisable.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

fda

Accession

0001701247-26-000012

Alert Tier

6